MedTrace Logo

Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Gastroenteritis in a Pediatric Emergency Department

NCT00120744 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2018-04-17

No results posted yet for this study

Summary

The objectives of the study were to determine whether ondansetron treatment would reduce:

* the amount of vomiting in the emergency department;
* the need for intravenous rehydration; and
* the need for hospitalization.

Conditions

Interventions

DRUG

Ondansetron Oral Disintegrating Tablet

Sponsors & Collaborators

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Ann & Robert H Lurie Children's Hospital of Chicago

    collaborator OTHER

  • The Hospital for Sick Children

    lead OTHER

Principal Investigators

  • Stephen B Freedman, MDCM, MSCI · The Hospital for Sick Children

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2005-04-30
Completion
2005-04-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00120744 on ClinicalTrials.gov